Significant POLB 001 Patent Granted in United StatesImmunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON,…
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the…
Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK /…
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company…
Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's DiseaseNovel therapeutic with Fast Track and Orphan DesignationLONDON, UK /…
Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…
UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad…
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage…
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti…
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is…